glp-1 and tamoxifen use linked to lower breast cancer incidence Breast cancer: GLP-1 use may

Community sources describe early signs including skin feeling more hydrated and minor improvements in elasticity

However, they have some distinct mechanisms of action and uses

[26] Individuals with severe liver disease or with a condition called metabolic acidosis are also contraindicated for Lipo-B

It expands access to GLP-1s beyond those with clinical obesity recognizing their potential benefits beyond weight alone

Note that this trial used semaglutide at 1.0 mg - the glycemic-management dose - rather than the 2.4 mg dose used for weight management (Wegovy)

The side effect profile is more serious than GLP1R agonists , including depression and suicidal ideation and it is not approved for other types of obesity